Press Releases

Date Title and Summary Additional Formats
Toggle Summary Conatus to Present at Upcoming Investor Conferences
SAN DIEGO, March 27, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the company's scheduled presentations at two upcoming investor conferences in New York: H.C. Wainwright NASH Investor Conference at 2:20 p.m. ET on Monday, April 3.
View HTML
Toggle Summary Conatus Pharmaceuticals Reports 2016 Financial Results and Program Updates
SAN DIEGO, March 15, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the fourth quarter and full year ended December 31, 2016, and provided updates on its clinical development programs. Conatus is developing emricasan, its first-in-class,
View HTML
Toggle Summary Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results
SAN DIEGO, March 08, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the fourth quarter and full year ended December 31, 2016, after the market close on Wednesday, March 15, 2017.
View HTML
Toggle Summary Conatus Pharmaceuticals Appoints William R. LaRue as Independent Board Member
SAN DIEGO, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced the appointment of William R. LaRue as an additional independent member to the Conatus Board of Directors. Mr. LaRue also will serve as Chair of the Audit Committee.
View HTML
Toggle Summary Conatus to Present at BIO CEO & Investor Conference
SAN DIEGO, Feb. 06, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Biotechnology Industry Organization (BIO) CEO & Investor Conference in New York at 2:30 p.m.
View HTML
Toggle Summary Conatus Pharmaceuticals Promotes Daniel L. Ripley to Senior Vice President, Business Development, Program and Alliance Management
SAN DIEGO , Feb. 02, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) announced today the promotion of Daniel L. Ripley to Senior Vice President, Business Development, Program and Alliance Management, effective immediately. Mr.
View HTML
Toggle Summary Conatus Announces Exclusive Worldwide Option, Collaboration and License Agreement Covering Development and Commercialization of Emricasan
- Conference Call and Webcast Presentation at 5:30 p.m. ET Today - - Continuing Initial Focus on NASH Cirrhosis with Parallel Development in NASH Fibrosis - - Full Funding in Position for Remaining Development of Emricasan - SAN DIEGO, Dec. 19, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc.
View HTML
Toggle Summary Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
- Emricasan Improves Liver Function in Cirrhosis Patients with NASH and/or Elevated MELD Scores - - Emricasan Improves Hepatic Blood Flow, Portal Hypertension, and Liver Function in Animal Models - SAN DIEGO , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc.
View HTML
Toggle Summary Conatus Pharmaceuticals to Present at Stifel 2016 Healthcare Conference
SAN DIEGO, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the Stifel 2016 Healthcare Conference in New York at 8:45 a.m. ET on Wednesday, November 16, 2016.
View HTML
Toggle Summary Conatus Pharmaceuticals Reports Third Quarter 2016 Financial Results and Program Updates
SAN DIEGO, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the quarter and nine months ended September 30, 2016,
View HTML